Paymohn Mahdavi, MD
Retina Specialist · Redlands, CANPI 1295095669
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,696 of the $1,983 with a category attached, or 85.5%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $688 and has fallen 77.8% since, to $153 in 2025. That places this record below the midpoint for retina specialist clinicians in CA, where the typical reported total is $3,667.
Across 50 payments — averaging $39.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ANI Pharmaceuticals, Inc.$473
- Notal Vision, Inc.$274
- Novartis$199
- AbbVie$196
- Genentech USA, Inc.$137
- Ivantis, Inc$135
- plus $569 from 13 others
Across 4 payments — averaging $3617.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$14K
What the payments were for
- Speaking & faculty fees$27414%
- Food & beverage$1,69685%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 3 | $473 |
| Notal Vision, Inc. | 1 | $274 |
| Novartis | 5 | $199 |
| AbbVie(2 entities) | 8 | $196 |
| Genentech USA, Inc. | 6 | $137 |
| Ivantis, Inc | 1 | $135 |
| Regeneron Healthcare Solutions, Inc. | 5 | $117 |
| Mallinckrodt Hospital Products Inc. | 4 | $101 |
| Biogen | 4 | $82 |
| Bausch & Lomb Americas Inc. | 3 | $64 |
| Eyepoint US, Inc. | 2 | $42 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURIFIED CORTROPHIN GEL$429
- Hydrus Microstent$135
- BEOVU$111
How this compares
$1,983 in reported general payments places this provider in the 30th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 760 | $34,000 |
| EyleaAflibercept | 14 | $27,339 |
| Bromfenac Sodium | 187 | $16,877 |
| RestasisCyclosporine | 15 | $15,730 |
| LumiganBimatoprost | 26 | $11,512 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $9,019 |
| RhopressaNetarsudil Mesylate | 21 | $8,683 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 528 | $7,989 |
| Ketorolac Tromethamine | 281 | $7,873 |
| Brimonidine Tartrate | 157 | $4,820 |
| ProlensaBromfenac Sodium | 11 | $3,866 |
| Latanoprost | 435 | $3,803 |
| Travoprost | 11 | $2,710 |
| Atropine Sulfate | 40 | $1,553 |
| Dorzolamide Hcl | 82 | $1,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $117 | $27,33914 claims |
| AbbVieRestasis, Lumigan | $196 | $27,24241 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $21 | $17,70346 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $21 | $3,86611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 187 retina specialist providers in California.
Other retina specialist in Redlands
- Eric ChinRedlands$11K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.